Assess the Incidence of Peripheral Neuropathy in Recently Diagnosed Cases of Type II Diabetes Mellitus
DOI:
https://doi.org/10.63682/jns.v13i1.8780Keywords:
Peripheral neuropathy, Type II Diabetes Mellitus, prevalence, obesity, age, early screeningAbstract
Background: Type II Diabetes Mellitus comes with a significant morbidity due to the common complication of peripheral neuropathy. It is vital to identify early in order to control and avoid more complications.
Objective: The purpose of this study was to assess the incidence of peripheral neuropathy in recently diagnosed cases of type ii diabetes mellitus
Material and Methods: This is a cross sectional study carried out at Sharif Medical and Dental College Lahore November 2022 to May 2024. 350 newly diagnosed Type II Diabetes Mellitus patients were recruited into the study. The Michigan Neuropathy Screening Instrument (MNSI) was used to assess peripheral neuropathy status. Age, BMI, symptom duration and hypertension status were collected as demographic and clinical data. Descriptive statistics and Chi square tests for categorical comparisons using p ≤ 0.05 were used on data analysis.
Results: The mean age of patients was 56.01 years (SD = 11.231), with a mean symptom duration of 12.53 weeks (SD = 6.921) and a mean BMI of 27.88 (SD = 3.605). The prevalence of peripheral neuropathy was 31.4% (n=110). A significant association was found between age and neuropathy, with prevalence increasing from 17.9% in the 35-49 age group to 41.0% in patients aged 65-74 years (p=0.001). Obesity was also significantly associated with neuropathy, with 56.6% of obese patients affected versus 19.4% of non-obese patients (p=0.000). No significant associations were observed for gender, hypertension, or symptom duration.
Conclusion: Peripheral neuropathy is prevalent in newly diagnosed Type II Diabetes Mellitus patients, particularly among older and obese individuals. Early screening and targeted interventions focused on these risk factors may help reduce neuropathy-related complications.
Downloads
Metrics
References
Loprinzi C, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology. 2020.
Handzlik MK, Gengatharan JM, Frizzi K, et al. Insulin-regulated serine and lipid metabolism drive peripheral neuropathy. Nature. 2023.
Jain A, Mg H, Sharique M, Redhwan MA. Chemotherapy-Induced Peripheral Neuropathy. Indian Journal of Pharmaceutical Education and Research. 2023.
Oaklander A, Mills AJ, Kelley M, et al. Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID. Neurology: Neuroimmunology & Neuroinflammation. 2022.
Elafros M, Andersen H, Bennett D, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. The Lancet Neurology. 2022.
Yang K, Wang Y, Li Y, et al. Progress in the treatment of diabetic peripheral neuropathy. Biomedicine & pharmacotherapy. 2022.
Akpoveso O, Ubah EE, Obasanmi G. Antioxidant Phytochemicals as Potential Therapy for Diabetic Complications. Antioxidants. 2023.
Wang W, Ji Q, Ran X, et al. Prevalence and risk factors of diabetic peripheral neuropathy: A population‐based cross‐sectional study in China. Diabetes/Metabolism Research and Reviews. 2023.
Reynolds L, Luo Z, Singh K. Diabetic complications and prospective immunotherapy. Frontiers in Immunology. 2023.
Shojima N, Yamauchi T. Progress in genetics of type 2 diabetes and diabetic complications. Journal of Diabetes Investigation. 2023.
Yar AA, Javed M, Shahzad M, Iqbal J, Aslam MI, Khan ZA. Frequency of peripheral neuropathy in newly diagnosed cases of type II diabetes mellitus. Professional Med J. 2021;28(10):1443-1446. https://doi.org/10.29309/TPMJ/2021.28.10.6210
Akram N, Butt A, Waheed K. Peripheral neuropathy in newly diagnosed cases of type II diabetes mellitus. Pakistan Journal Of Neurological Surgery. 2019;23(3):234-238.
Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves.” Endocrine and Metabolic Science. 2020;1(1-2):100053.
Akhtar S, Hassan F, Saqlain SR, Ali A, Hussain S. The prevalence of peripheral neuropathy among the patients with diabetes in Pakistan: a systematic review and meta-analysis. Scientific Reports. 2023;13(1):11744.
Jadhao P, Swain J, Das S, Mangaraj S, Sravya SL. Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients. Current Diabetes Reviews. 2024.
Kebede SA, Tusa BS, Weldesenbet AB, Tessema ZT, Ayele TA. Time to diabetic neuropathy and its predictors among newly diagnosed type 2 diabetes mellitus patients in Northwest Ethiopia. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2021;57:1-7.
Tahir MM, Chachar AZK, Haider M, Shamim A, Asif M, Ali S, Ali S. Frequency of Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Presenting in a Tertiary Care Hospital of Lahore. Pak J Med Health Sci. 2021;15(7):1676-1679.
Shahid I, Wajahat A, Muhammad MG, Rubab S, Mohammad IS, Hira AM. Frequency of Peripheral Neuropathy in Newly Diagnosed Cases of Type II Diabetes Mellitus. Pak J Med Health Sci. 2021;15(1):679-681.
Ali Lakhiar M, Naeem Shahbaz N, Hafeez Bughio A, Prakash J. Frequency of peripheral neuropathy in newly diagnosed patients of diabetes mellitus type II on clinical and electrophysiological basis. Pakistan Journal of Neurological Sciences (PJNS). 2014;9(4):31-35.
Jadhao P, Swain J, Das S, Mangaraj S, Sravya SL. Prevalence and Predictors of Diabetic Peripheral Neuropathy in Newly Diagnosed Type 2 Diabetes Mellitus Patients. Current Diabetes Reviews. 2024.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
